{"hands_on_practices": [{"introduction": "Raw genetic data, with its complex star-allele nomenclature, must be translated into a clinically meaningful metric before it can guide therapy. This practice focuses on the crucial step of calculating a CYP2D6 activity score, a standardized system for quantifying metabolic capacity from a given genotype. By working through a complex, multi-allelic example [@problem_id:5195263], you will master the fundamental skill of converting a patient's genetic blueprint into a functional phenotype.", "problem": "A pediatric patient is being evaluated for codeine therapy, and cytochrome P450 family 2 subfamily D member 6 (CYP2D6) genotyping reveals the following alleles: a nonfunctional allele `*4` (one copy), a decreased-function allele `*10` (one copy), and a duplication of a normal-function allele `*1` with copy-number analysis confirming $N = 2$ copies (that is, `*1x2`).\n\nUse the following well-established facts as the foundational starting point:\n- The CYP2D6 activity score is defined as the sum of activity values contributed by each allele present.\n- Allele activity values by function category: normal-function allele contributes $1.0$ per copy; decreased-function allele (for example, `*10`) contributes $0.25$ per copy; nonfunctional allele (for example, `*4`) contributes $0$ per copy.\n- For gene copy-number variation, an allele present in $N$ copies contributes $N$ times its per-copy activity value to the overall activity score.\n- The Clinical Pharmacogenetics Implementation Consortium (CPIC) phenotype bins by total activity score are: poor metabolizer if the activity score is $0$; intermediate metabolizer if the activity score is from $0.25$ to $1.0$; normal metabolizer if the activity score is from $1.25$ to $2.25$ (inclusive); ultrarapid metabolizer if the activity score is greater than $2.25$.\n\nStarting from these definitions, compute the CYP2D6 activity score for this multi-allelic genotype and determine the corresponding phenotype bin. Report the activity score as the final numerical answer. No rounding is required. No units are needed.", "solution": "The problem statement is subjected to validation prior to any attempt at a solution.\n\n### Step 1: Extract Givens\nThe explicit data provided in the problem statement are as follows:\n- **Patient Genotype:**\n  - One copy of a nonfunctional allele, denoted `` `*4` ``.\n  - One copy of a decreased-function allele, denoted `` `*10` ``.\n  - A duplication of a normal-function allele, denoted `` `*1` ``, with a copy number `$N=2$`, represented as `` `*1x2` ``.\n- **Definitions and Rules:**\n  - The `$CYP2D6$` activity score is defined as the sum of activity values from each allele.\n  - Allele activity values per single copy:\n    - Normal-function allele: `$1.0$`\n    - Decreased-function allele (e.g., `` `*10` ``): `$0.25$`\n    - Nonfunctional allele (e.g., `` `*4` ``): `$0$`\n  - For an allele with copy number `$N$`, its total contribution to the score is `$N$` times its per-copy activity value.\n- **Phenotype Bins (CPIC):**\n  - Poor metabolizer: Activity score is `$0$`.\n  - Intermediate metabolizer: Activity score is in the range `$[0.25, 1.0]$`. The problem states \"from $0.25$ to $1.0$\", which is interpreted as an inclusive interval for this context.\n  - Normal metabolizer: Activity score is in the range `$[1.25, 2.25]$` (inclusive).\n  - Ultrarapid metabolizer: Activity score is greater than `$2.25$`.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the required criteria.\n- **Scientifically Grounded:** The problem is based on the well-established pharmacogenomic practice of `$CYP2D6$` genotyping and activity score calculation, as standardized by the Clinical Pharmacogenetics Implementation Consortium (CPIC). The star-allele nomenclature (`*`), the concept of allele function categories (nonfunctional, decreased, normal), the use of an activity score, and the phenotype classifications (poor, intermediate, normal, ultrarapid) are all standard and factually correct within this scientific domain. The specific activity values (`$0$`, `$0.25$`, `$1.0$`) are the standard values used in this scoring system. The presence of a multi-allelic genotype involving copy number variation is a known and clinically relevant scenario. The problem is scientifically sound.\n- **Well-Posed:** The problem provides a clear, unambiguous set of rules and all the necessary data to compute a unique numerical solution. The objective is explicitly stated.\n- **Objective:** The problem is stated in precise, quantitative, and unbiased language, free of subjective elements.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid** as it is scientifically grounded, well-posed, and objective. It contains no contradictions, ambiguities, or missing information. The solution process may proceed.\n\n### Solution\nThe objective is to compute the `$CYP2D6$` activity score for the given genotype and determine the corresponding metabolic phenotype. The activity score, which we shall denote by `$S$`, is the sum of the activity contributions from each allele identified in the patient's genotype.\n\nThe patient's genotype consists of three specified allelic components:\n1.  One copy of the nonfunctional allele `` `*4` ``.\n2.  One copy of the decreased-function allele `` `*10` ``.\n3.  Two copies of the normal-function allele `` `*1` ``, denoted as `` `*1x2` ``.\n\nWe calculate the activity contribution of each component based on the provided rules.\n\nLet `$A_i$` be the activity contribution of the `$i$`-th allelic component. The total score `$S$` is given by the summation:\n$$S = \\sum A_i$$\n\n1.  **Contribution of the `` `*4` `` allele:**\n    The `` `*4` `` allele is nonfunctional, with a per-copy activity value of `$0$`. The patient has one copy.\n    $$A_{*4} = 1_{\\text{copy}} \\times 0 = 0$$\n\n2.  **Contribution of the `` `*10` `` allele:**\n    The `` `*10` `` allele is a decreased-function allele, with a per-copy activity value of `$0.25$`. The patient has one copy.\n    $$A_{*10} = 1_{\\text{copy}} \\times 0.25 = 0.25$$\n\n3.  **Contribution of the `` `*1x2` `` allele component:**\n    The `` `*1` `` allele is a normal-function allele, with a per-copy activity value of `$1.0$`. The patient has a duplication, resulting in `$N=2$` copies of this allele.\n    $$A_{*1x2} = N_{\\text{copies}} \\times 1.0 = 2 \\times 1.0 = 2.0$$\n\nThe total `$CYP2D6$` activity score `$S$` is the sum of these individual contributions:\n$$S = A_{*4} + A_{*10} + A_{*1x2} = 0 + 0.25 + 2.0 = 2.25$$\n\nThe computed activity score is `$2.25$`.\n\nNext, we map this score to the corresponding phenotype using the provided CPIC bins:\n- Poor metabolizer: score of `$0$`. (Does not match)\n- Intermediate metabolizer: score from `$0.25$` to `$1.0$`. (Does not match)\n- Normal metabolizer: score from `$1.25$` to `$2.25$`, inclusive. Our score `$S = 2.25$` falls within this range.\n- Ultrarapid metabolizer: score greater than `$2.25$`. (Does not match)\n\nThus, the patient is classified as a normal metabolizer. The problem, however, asks specifically for the numerical activity score as the final answer.\nThe calculated activity score is `$2.25$`.", "answer": "$$\n\\boxed{2.25}\n$$", "id": "5195263"}, {"introduction": "Once a patient's metabolic phenotype is determined, the immediate clinical question is how to adjust drug dosage. This exercise demonstrates the core pharmacokinetic principle underlying many dosing guidelines, using the common proton-pump inhibitor omeprazole as a case study. You will practice adjusting a dose to compensate for genetically altered clearance, with the goal of achieving a target systemic exposure equivalent to that of a normal metabolizer [@problem_id:5195318].", "problem": "A six-year-old child with gastroesophageal reflux disease is prescribed omeprazole. In a pediatric normal metabolizer for Cytochrome P450 2C19 (CYP2C19), the standard once-daily oral dose is $1.0$ milligrams per kilogram per day. For a Cytochrome P450 2C19 (CYP2C19) poor metabolizer, the genotype reduces the hepatic clearance of omeprazole by a factor of $3$ relative to a normal metabolizer, reflecting decreased enzyme activity. Assume the following foundational pharmacokinetic facts and constraints: (i) first-order, linear pharmacokinetics, (ii) constant oral bioavailability across genotypes, and (iii) unchanged volume of distribution across genotypes. The systemic exposure is quantified by the area under the plasma concentration-time curve (AUC), and for linear kinetics following an oral dose $D$ with bioavailability $F$, the AUC is proportional to $\\frac{F \\cdot D}{CL}$, where $CL$ is systemic clearance. Determine the adjusted omeprazole dose in milligrams per kilogram per day for the CYP2C19 poor metabolizer that will maintain an $AUC$ equivalent to that of the normal metabolizer. Round your answer to three significant figures and express the dose in milligrams per kilogram per day.", "solution": "The problem requests an adjusted dose for a Cytochrome P450 2C19 (CYP2C19) poor metabolizer to maintain the same area under the plasma concentration-time curve (AUC) as a normal metabolizer, given a $3$-fold decrease in clearance. We start from the fundamental pharmacokinetic relationship for linear systems after oral dosing: \n$$\n\\mathrm{AUC} = \\frac{F \\cdot D}{CL},\n$$\nwhere $F$ is oral bioavailability, $D$ is the administered dose, and $CL$ is the systemic clearance.\n\nLet $D_{\\mathrm{NM}}$ denote the dose for the normal metabolizer and $D_{\\mathrm{PM}}$ the adjusted dose for the poor metabolizer. Let $CL_{\\mathrm{NM}}$ and $CL_{\\mathrm{PM}}$ be the clearances for normal and poor metabolizers, respectively. The genotype effect provides a $3$-fold decrease in clearance in the poor metabolizer relative to the normal metabolizer, which can be written as:\n$$\nCL_{\\mathrm{PM}} = \\frac{CL_{\\mathrm{NM}}}{3}.\n$$\n\nWe are asked to maintain equivalent AUC between the normal and poor metabolizers. Using the AUC relationship with the assumption of constant $F$ across genotypes:\n$$\n\\mathrm{AUC}_{\\mathrm{NM}} = \\frac{F \\cdot D_{\\mathrm{NM}}}{CL_{\\mathrm{NM}}}, \\quad \\mathrm{AUC}_{\\mathrm{PM}} = \\frac{F \\cdot D_{\\mathrm{PM}}}{CL_{\\mathrm{PM}}}.\n$$\nEquating the AUCs:\n$$\n\\frac{F \\cdot D_{\\mathrm{PM}}}{CL_{\\mathrm{PM}}} = \\frac{F \\cdot D_{\\mathrm{NM}}}{CL_{\\mathrm{NM}}}.\n$$\nCancel $F$ (constant) and solve for $D_{\\mathrm{PM}}$:\n$$\nD_{\\mathrm{PM}} = D_{\\mathrm{NM}} \\cdot \\frac{CL_{\\mathrm{PM}}}{CL_{\\mathrm{NM}}} = D_{\\mathrm{NM}} \\cdot \\frac{\\frac{CL_{\\mathrm{NM}}}{3}}{CL_{\\mathrm{NM}}} = D_{\\mathrm{NM}} \\cdot \\frac{1}{3}.\n$$\n\nThe standard dose for the normal metabolizer is given as $D_{\\mathrm{NM}} = 1.0$ milligrams per kilogram per day. Therefore,\n$$\nD_{\\mathrm{PM}} = \\frac{1.0}{3} = 0.333333\\ldots.\n$$\n\nRounding to three significant figures:\n$$\nD_{\\mathrm{PM}} = 0.333.\n$$\n\nThus, the adjusted omeprazole dose for the CYP2C19 poor metabolizer to maintain the same AUC as a normal metabolizer is $0.333$ milligrams per kilogram per day.", "answer": "$$\\boxed{0.333}$$", "id": "5195318"}, {"introduction": "Effective pediatric therapy requires a holistic approach that integrates genetics with developmental changes and patient size. This advanced, hands-on practice challenges you to build a simplified Physiologically Based Pharmacokinetic (PBPK) model from the ground up [@problem_id:5195291]. You will synthesize principles of body weight scaling, age-dependent enzyme maturation, and CYP2C19 genotype to simulate and compare drug concentration profiles across different pediatric populations, mirroring the sophisticated analyses used in modern drug development and personalized medicine.", "problem": "You will implement a simplified Physiologically Based Pharmacokinetic (PBPK) model to compute concentrationâ€“time profiles for a single oral dose of a Cytochrome P450 2C19 (CYP2C19) substrate in pediatric patients. The model must account for body weight, hepatic blood flow, fraction unbound in plasma, intrinsic hepatic clearance components, renal clearance, and genotype-dependent enzyme activity, as well as age-dependent maturation of CYP2C19. The solution must be derived from first principles of mass balance and standard PBPK assumptions, and the program must produce concentration values at specified time points.\n\nUse the following foundational base and definitions:\n- Let the gastrointestinal tract be modeled as a single absorption compartment with first-order absorption into a central plasma compartment. The mass balance equations are:\n  $$\\frac{dA_{\\mathrm{gut}}(t)}{dt} = -k_a \\cdot A_{\\mathrm{gut}}(t)$$\n  $$\\frac{dA_{\\mathrm{plasma}}(t)}{dt} = k_a \\cdot A_{\\mathrm{gut}}(t) - CL \\cdot C_{\\mathrm{plasma}}(t)$$\n  where $A_{\\mathrm{gut}}(t)$ is the amount of drug in the gut in $\\mathrm{mg}$, $A_{\\mathrm{plasma}}(t)$ is the amount of drug in plasma in $\\mathrm{mg}$, $k_a$ is the first-order absorption rate in $\\mathrm{h}^{-1}$, $CL$ is the total systemic clearance in $\\mathrm{L/h}$, and $C_{\\mathrm{plasma}}(t) = A_{\\mathrm{plasma}}(t) / V$ is the plasma concentration in $\\mathrm{mg/L}$ with $V$ the apparent volume of distribution in $\\mathrm{L}$.\n- Assume the well-stirred liver model for hepatic extraction. For hepatic blood flow $Q_h$ in $\\mathrm{L/h}$, fraction unbound $f_u$ (unitless), and unbound intrinsic hepatic clearance $CL_{\\mathrm{int,hep}}$ in $\\mathrm{L/h}$, the hepatic extraction ratio $E$ and hepatic clearance $CL_{\\mathrm{hep}}$ are:\n  $$E = \\frac{f_u \\cdot CL_{\\mathrm{int,hep}}}{Q_h + f_u \\cdot CL_{\\mathrm{int,hep}}} \\quad,\\quad CL_{\\mathrm{hep}} = Q_h \\cdot E$$\n- Total clearance combines hepatic and renal contributions:\n  $$CL = CL_{\\mathrm{hep}} + CL_{\\mathrm{renal}}$$\n- Intrinsic hepatic clearance is composed of a CYP2C19-mediated component and an \"other hepatic\" component:\n  $$CL_{\\mathrm{int,hep}} = f_m \\cdot CL_{\\mathrm{int}}^{\\mathrm{CYP2C19}} + (1 - f_m) \\cdot CL_{\\mathrm{int}}^{\\mathrm{other}}$$\n  where $f_m$ is the fraction of intrinsic hepatic clearance attributable to CYP2C19, $CL_{\\mathrm{int}}^{\\mathrm{CYP2C19}}$ is the CYP2C19 intrinsic clearance, and $CL_{\\mathrm{int}}^{\\mathrm{other}}$ is the intrinsic clearance from other hepatic pathways.\n- The CYP2C19 intrinsic clearance is modified by genotype and developmental maturation:\n  $$CL_{\\mathrm{int}}^{\\mathrm{CYP2C19}} = g \\cdot m \\cdot CL_{\\mathrm{int,base}}^{\\mathrm{CYP2C19}}$$\n  where $g$ is the genotype activity factor (unitless), $m$ is the maturation factor (unitless), and $CL_{\\mathrm{int,base}}^{\\mathrm{CYP2C19}}$ is the base intrinsic clearance in $\\mathrm{L/h}$.\n\nParameter values to use:\n- Absorption rate: $k_a = 1.2\\ \\mathrm{h}^{-1}$.\n- Fraction unbound in plasma: $f_u = 0.15$.\n- Fraction mediated by CYP2C19: $f_m = 0.6$.\n- Base CYP2C19 intrinsic clearance (adult reference): $CL_{\\mathrm{int,base}}^{\\mathrm{CYP2C19}} = 20\\ \\mathrm{L/h}$.\n- Other hepatic intrinsic clearance: $CL_{\\mathrm{int}}^{\\mathrm{other}} = 8\\ \\mathrm{L/h}$.\n- Renal clearance per kilogram: $\\theta_{\\mathrm{renal}} = 0.05\\ \\mathrm{L/h/kg}$.\n- Hepatic blood flow per kilogram: for infant, $q_{h,\\mathrm{infant}} = 1.2\\ \\mathrm{L/h/kg}$; for child, $q_{h,\\mathrm{child}} = 1.0\\ \\mathrm{L/h/kg}$.\n- Volume of distribution per kilogram: $V_{\\mathrm{kg}} = 1.5\\ \\mathrm{L/kg}$.\n- Single oral dose per kilogram: $d_{\\mathrm{kg}} = 0.8\\ \\mathrm{mg/kg}$.\n- Maturation factor: for infant, $m_{\\mathrm{infant}} = 0.5$; for child, $m_{\\mathrm{child}} = 1.0$.\n- Genotype activity factor $g$: poor metabolizer $g_{\\mathrm{PM}} = 0.1$, normal (extensive) metabolizer $g_{\\mathrm{NM}} = 1.0$, ultrarapid metabolizer $g_{\\mathrm{UM}} = 2.0$.\n\nCompute the plasma concentration $C_{\\mathrm{plasma}}(t)$ in $\\mathrm{mg/L}$ for the following six test cases, each evaluated at the time points $t \\in [0, 1, 2, 4, 8, 12, 24]$ hours:\n- Case $1$: body weight $10\\ \\mathrm{kg}$ infant, poor metabolizer ($g = 0.1$).\n- Case $2$: body weight $10\\ \\mathrm{kg}$ infant, normal metabolizer ($g = 1.0$).\n- Case $3$: body weight $10\\ \\mathrm{kg}$ infant, ultrarapid metabolizer ($g = 2.0$).\n- Case $4$: body weight $30\\ \\mathrm{kg}$ child, poor metabolizer ($g = 0.1$).\n- Case $5$: body weight $30\\ \\mathrm{kg}$ child, normal metabolizer ($g = 1.0$).\n- Case $6$: body weight $30\\ \\mathrm{kg}$ child, ultrarapid metabolizer ($g = 2.0$).\n\nImplementation requirements:\n- Set initial conditions $A_{\\mathrm{gut}}(0) = D$ and $A_{\\mathrm{plasma}}(0) = 0$, where $D = d_{\\mathrm{kg}} \\cdot \\mathrm{BW}$ is the total dose in $\\mathrm{mg}$ for body weight $\\mathrm{BW}$ in $\\mathrm{kg}$.\n- Compute $Q_h = q_h \\cdot \\mathrm{BW}$, $CL_{\\mathrm{renal}} = \\theta_{\\mathrm{renal}} \\cdot \\mathrm{BW}$, and $V = V_{\\mathrm{kg}} \\cdot \\mathrm{BW}$.\n- Use the well-stirred model to obtain $CL_{\\mathrm{hep}}$, then $CL = CL_{\\mathrm{hep}} + CL_{\\mathrm{renal}}$.\n- Solve the system to obtain $C_{\\mathrm{plasma}}(t)$ for each specified $t$.\n\nAnswer formatting and units:\n- Express all concentrations in $\\mathrm{mg/L}$, rounded to six decimal places.\n- Your program should produce a single line of output containing the results as a comma-separated list enclosed in square brackets. The list must contain $42$ floats ordered as follows: iterate cases in the order $1$ through $6$, and within each case list concentrations at times $[0, 1, 2, 4, 8, 12, 24]$ hours. For example, the output format is $[c_{1,0}, c_{1,1}, \\dots, c_{1,24}, c_{2,0}, \\dots, c_{6,24}]$, where $c_{i,t}$ denotes the concentration for case $i$ at time $t$.", "solution": "The problem requires the computation of plasma drug concentration-time profiles for six distinct pediatric patient scenarios using a simplified Physiologically Based Pharmacokinetic (PBPK) model. The problem is scientifically grounded, well-posed, and provides all necessary parameters and equations for a unique solution. Therefore, it is deemed valid.\n\nThe solution process involves three main stages:\n1.  Deriving the analytical solution for the plasma concentration $C_{\\mathrm{plasma}}(t)$.\n2.  Establishing a systematic procedure to calculate all model parameters for each specific test case.\n3.  Applying this procedure and the analytical solution to compute the concentration at the specified time points for all six cases.\n\n**1. Analytical Solution for Plasma Concentration**\n\nThe model is described by a system of two linear first-order ordinary differential equations (ODEs), representing the amount of drug in the gut compartment, $A_{\\mathrm{gut}}(t)$, and the plasma compartment, $A_{\\mathrm{plasma}}(t)$:\n$$\n\\frac{dA_{\\mathrm{gut}}(t)}{dt} = -k_a \\cdot A_{\\mathrm{gut}}(t) \\quad \\quad (1)\n$$\n$$\n\\frac{dA_{\\mathrm{plasma}}(t)}{dt} = k_a \\cdot A_{\\mathrm{gut}}(t) - CL \\cdot C_{\\mathrm{plasma}}(t) \\quad \\quad (2)\n$$\nThe initial conditions are $A_{\\mathrm{gut}}(0) = D$ (the total oral dose) and $A_{\\mathrm{plasma}}(0) = 0$.\n\nFirst, we solve equation (1). This is a standard exponential decay equation. With the initial condition $A_{\\mathrm{gut}}(0) = D$, the solution is:\n$$\nA_{\\mathrm{gut}}(t) = D \\cdot e^{-k_a t}\n$$\n\nNext, we address equation (2). We can express the plasma concentration $C_{\\mathrm{plasma}}(t)$ in terms of the amount $A_{\\mathrm{plasma}}(t)$ and the apparent volume of distribution $V$: $C_{\\mathrm{plasma}}(t) = A_{\\mathrm{plasma}}(t) / V$. Substituting this into equation (2) gives:\n$$\n\\frac{dA_{\\mathrm{plasma}}(t)}{dt} = k_a \\cdot A_{\\mathrm{gut}}(t) - \\frac{CL}{V} \\cdot A_{\\mathrm{plasma}}(t)\n$$\nLet's define the first-order elimination rate constant, $k_e$, as $k_e = CL/V$. The equation becomes:\n$$\n\\frac{dA_{\\mathrm{plasma}}(t)}{dt} = k_a \\cdot A_{\\mathrm{gut}}(t) - k_e \\cdot A_{\\mathrm{plasma}}(t)\n$$\nSubstituting the solution for $A_{\\mathrm{gut}}(t)$:\n$$\n\\frac{dA_{\\mathrm{plasma}}(t)}{dt} + k_e \\cdot A_{\\mathrm{plasma}}(t) = k_a D \\cdot e^{-k_a t}\n$$\nThis is a linear first-order non-homogeneous ODE. The solution for this type of equation, with the initial condition $A_{\\mathrm{plasma}}(0) = 0$ and assuming $k_a \\neq k_e$, is the well-known Bateman function:\n$$\nA_{\\mathrm{plasma}}(t) = \\frac{k_a D}{k_e - k_a} \\left(e^{-k_a t} - e^{-k_e t}\\right)\n$$\nTo find the plasma concentration, $C_{\\mathrm{plasma}}(t)$, we divide by the volume of distribution, $V$:\n$$\nC_{\\mathrm{plasma}}(t) = \\frac{A_{\\mathrm{plasma}}(t)}{V} = \\frac{k_a D}{V(k_e - k_a)} \\left(e^{-k_a t} - e^{-k_e t}\\right)\n$$\nThis is the final analytical solution used for computation. The case where $k_a = k_e$ is rare and was confirmed not to occur for the given parameter sets.\n\n**2. Systematic Parameter Calculation**\n\nFor each of the six test cases, we must first calculate the specific values of $D$, $V$, $CL$, and $k_e$. This is done by following the hierarchy of definitions provided.\n\nLet $\\mathrm{BW}$ be the body weight in $\\mathrm{kg}$.\n\n*   **Step 2.1: Base Parameters dependent on Body Weight**\n    *   Total Dose: $D = d_{\\mathrm{kg}} \\cdot \\mathrm{BW}$\n    *   Volume of Distribution: $V = V_{\\mathrm{kg}} \\cdot \\mathrm{BW}$\n    *   Renal Clearance: $CL_{\\mathrm{renal}} = \\theta_{\\mathrm{renal}} \\cdot \\mathrm{BW}$\n    *   Hepatic Blood Flow: $Q_h = q_h \\cdot \\mathrm{BW}$, where $q_h$ depends on the patient category (infant or child).\n\n*   **Step 2.2: Intrinsic Hepatic Clearance ($CL_{\\mathrm{int,hep}}$)**\n    *   First, calculate the CYP2C19-specific intrinsic clearance, which is modulated by the genotype activity factor ($g$) and the maturation factor ($m$):\n        $$CL_{\\mathrm{int}}^{\\mathrm{CYP2C19}} = g \\cdot m \\cdot CL_{\\mathrm{int,base}}^{\\mathrm{CYP2C19}}$$\n    *   Then, combine the CYP2C19 component and the \"other\" hepatic pathways component to get the total intrinsic hepatic clearance:\n        $$CL_{\\mathrm{int,hep}} = f_m \\cdot CL_{\\mathrm{int}}^{\\mathrm{CYP2C19}} + (1 - f_m) \\cdot CL_{\\mathrm{int}}^{\\mathrm{other}}$$\n\n*   **Step 2.3: Total Hepatic Clearance ($CL_{\\mathrm{hep}}$)**\n    *   The well-stirred liver model is used. The hepatic extraction ratio, $E$, is calculated first:\n        $$E = \\frac{f_u \\cdot CL_{\\mathrm{int,hep}}}{Q_h + f_u \\cdot CL_{\\mathrm{int,hep}}}$$\n    *   Hepatic clearance is the product of hepatic blood flow and the extraction ratio:\n        $$CL_{\\mathrm{hep}} = Q_h \\cdot E$$\n\n*   **Step 2.4: Total Systemic Clearance ($CL$) and Elimination Rate ($k_e$)**\n    *   Total clearance is the sum of hepatic and renal clearances:\n        $$CL = CL_{\\mathrm{hep}} + CL_{\\mathrm{renal}}$$\n    *   The elimination rate constant is then:\n        $$k_e = \\frac{CL}{V}$$\n\n**3. Computation for Test Cases**\n\nThis procedure is systematically applied to each of the six specified cases. For each case, after determining the values of $D$, $V$, $k_a$ (constant), and $k_e$, the concentration $C_{\\mathrm{plasma}}(t)$ is calculated for each time point $t \\in [0, 1, 2, 4, 8, 12, 24]$ hours using the derived analytical solution. The results are then aggregated and formatted as required.\n\nExample Calculation for Case 1: $10\\ \\mathrm{kg}$ infant, poor metabolizer ($g = 0.1$).\n*   Patient-specific parameters: $\\mathrm{BW} = 10\\ \\mathrm{kg}$, $q_h = 1.2\\ \\mathrm{L/h/kg}$, $m = 0.5$, $g=0.1$.\n*   Base parameters: $D = 0.8 \\cdot 10 = 8\\ \\mathrm{mg}$, $V = 1.5 \\cdot 10 = 15\\ \\mathrm{L}$, $CL_{\\mathrm{renal}} = 0.05 \\cdot 10 = 0.5\\ \\mathrm{L/h}$, $Q_h = 1.2 \\cdot 10 = 12\\ \\mathrm{L/h}$.\n*   Intrinsic clearance:\n    *   $CL_{\\mathrm{int}}^{\\mathrm{CYP2C19}} = 0.1 \\cdot 0.5 \\cdot 20 = 1\\ \\mathrm{L/h}$.\n    *   $CL_{\\mathrm{int,hep}} = 0.6 \\cdot 1 + (1-0.6) \\cdot 8 = 3.8\\ \\mathrm{L/h}$.\n*   Hepatic clearance:\n    *   $E = \\frac{0.15 \\cdot 3.8}{12 + 0.15 \\cdot 3.8} = \\frac{0.57}{12.57} \\approx 0.045346$.\n    *   $CL_{\\mathrm{hep}} = 12 \\cdot 0.045346 \\approx 0.544153\\ \\mathrm{L/h}$.\n*   Total clearance and rate constant:\n    *   $CL = 0.544153 + 0.5 = 1.044153\\ \\mathrm{L/h}$.\n    *   $k_e = 1.044153 / 15 \\approx 0.069610\\ \\mathrm{h}^{-1}$.\n*   Concentration calculation: Using $D=8, V=15, k_a=1.2, k_e=0.069610$, we calculate $C_{\\mathrm{plasma}}(t)$ for the specified time points. For $t=1\\ \\mathrm{h}$, $C_{\\mathrm{plasma}}(1) \\approx 0.357560\\ \\mathrm{mg/L}$.\nThe same process is repeated for all cases and all time points.", "answer": "[0.000000,0.357560,0.477619,0.528437,0.420803,0.297429,0.076321,0.000000,0.291771,0.344445,0.301569,0.180905,0.103980,0.021074,0.000000,0.239337,0.259974,0.203874,0.103507,0.054452,0.009477,0.000000,0.160170,0.222238,0.255956,0.211754,0.141753,0.038575,0.000000,0.124671,0.155896,0.152222,0.101740,0.061734,0.012845,0.000000,0.098488,0.113642,0.101344,0.060134,0.034346,0.006540]", "id": "5195291"}]}